MMW - Fortschritte der Medizin

, Volume 156, Issue 7, pp 38–41 | Cite as

Kennen Sie die sieben Todsünden?

Unverzeihliche Verordnungsfehler bei eingeschränkter Nierenfunktion
FORTBILDUNG_SCHWERPUNKT
  • 45 Downloads

Es bleibt wohl einem Protestanten vorbehalten, die Todsünde (peccatum mortiferum) in den Bereich der Medizin zu übertragen. Unverzeihliche Fehler bei der Auswahl und/oder Dosierung von Medikamenten können aber bei Patienten mit chronischer Nierenkrankheit dramatische Folgen haben, die bis zum Tode führen.

Keywords - The deadly sins of pharmacotherapy in chronic kidney disease

Glomerular filtraton rate hyperkalemia acute kidney injury dialysis 

Literatur

  1. 1.
    Grams ME, Juraschek SP, Selvin E et al. Trends in the Prevalence of Reduced GFR in the United States: A Comparison of Creatinine- and Cystatin C-Based Estimates. Am J Kidney Dis 2013; 62: 253–260PubMedCrossRefGoogle Scholar
  2. 2.
    Levey AS, Stevens LA, Hostetter T. Automatic reporting of estimated glomerular filtration rate—just what the doctor ordered. Clin Chem 2006; 52: 2188–2193PubMedCrossRefGoogle Scholar
  3. 3.
    Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013; 158: 825–830PubMedCrossRefGoogle Scholar
  4. 4.
    Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Stevens LA, Manzi J, Levey AS et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis 2007; 50: 21–35PubMedCrossRefGoogle Scholar
  6. 6.
    Shlipak MG, Matsushita K, Arnlov J et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932–943PubMedCrossRefGoogle Scholar
  7. 7.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47–56PubMedCrossRefGoogle Scholar
  8. 8.
    Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337–414CrossRefGoogle Scholar
  9. 9.
    Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140PubMedCrossRefGoogle Scholar
  10. 10.
    Fried LF, Emanuele N, Zhang JH et al. Combined Angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892–1903PubMedCrossRefGoogle Scholar
  11. 11.
    Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551PubMedCrossRefGoogle Scholar
  12. 12.
    Coca SG, Garg AX, Swaminathan M et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 2013; 28: 2787–2799PubMedCrossRefGoogle Scholar
  13. 13.
    Bahte SK, Hiss M, Lichtinghagen R, Kielstein JT. A missed opportunity — consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient BMC Nephrology doi: 10.1186/1471-2369-15-49
  14. 14.
    Eyler RF, Mueller BA. Antibiotic pharmacokinetic and pharmacodynamic considerations in patients with kidney disease. Adv Chronic Kidney Dis 2010; 17: 392–403PubMedCrossRefGoogle Scholar
  15. 15.
    Kielstein JT, Fliser D. Diuretika - tubuläre Wirkmechanismen und nephrologische Indikationen. Der Nephrologe 2008; 3: 384–393CrossRefGoogle Scholar
  16. 16.
    Patterson BD, Flores HC, Krueger J et al. Use of Proton Pump Inhibitors With Lack of Diagnostic Indications in 22 Midwestern US Skilled Nursing Facilities. J Am Med Dir Assoc 2013; 14: 429–432CrossRefGoogle Scholar
  17. 17.
    Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089–1096PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Bauersachs RM. [New oral anticoagulants and chronic kidney disease]. Internist (Berl) 2012; 53: 1431–1444CrossRefGoogle Scholar
  19. 19.
    Kruger T, Brandenburg V, Schlieper G, Marx N, Floege J. Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 2013; 28: 534–541PubMedCrossRefGoogle Scholar
  20. 20.
    Matzke GR, Aronoff GR, Atkinson AJ, Jr. et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 1122–1137PubMedCrossRefGoogle Scholar
  21. 21.
    Kielstein JT, Keller F. [Pharmacotherapy in patients suffering from chronic kidney disease]. Internist (Berl) 2012; 53: 802–809CrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  1. 1.Klinik für Nieren- und HochdruckerkrankungenMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations